Catalyst announces NCCN Guidelines for SCLC include new additions

Catalyst Pharmaceuticals (CPRX) announced the National Comprehensive Cancer Network, NCCN, Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer, SCLC, now include new additions involving Lambert Eaton myasthenic syndrome, LEMS, amifampridine, and the tests for PQ- and N-type voltage-gated calcium channel, VGCC, antibodies. The updated NCCN Clinical Practice Guidelines in Oncology for SCLC relating to LEMS now include symptom specificity-characterized by proximal muscle weakness and autonomic dysfunction. Under “Signs and Symptoms of Small Cell Lung Cancer,” the guidelines recommend diagnosis through a neurological evaluation, ideally in consultation with a neurologist, which may include testing for PQ- and N-type VGCC antibodies. Additionally, under “Principles of Supportive Care,” the guidelines recommend that amifampridine should be considered as a treatment in consultation with neurology.